Your session is about to expire
← Back to Search
Chemotherapy Combination for Cancer (I-FLOAT Trial)
I-FLOAT Trial Summary
This trial will test if it's safe to combine different chemotherapies to see if they work better together than alone.
I-FLOAT Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowI-FLOAT Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2016 Phase 4 trial • 128 Patients • NCT01588990I-FLOAT Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My blood counts and liver/kidney functions are within the required ranges.I have had radiation therapy for cancer before.I have not had major surgery in the last 4 weeks.I have experienced mild to severe diarrhea.I am willing to change my current medications to avoid interactions with irinotecan.My cancer can be either visible on scans or not.I am currently experiencing uncontrolled bleeding.I experience significant numbness or pain due to nerve damage.I do not have severe health or mental conditions that would make treatment risky.I have brain metastases confirmed by tests.I can do light work but not heavy physical activities.I am 18 years old or older.I had chemotherapy for metastatic disease less than 6 months before my current treatment.I am taking pancreatic enzyme replacements due to my pancreatic cancer.I have a confirmed advanced or spreading cancer in my digestive system.My jaundice from a tumor was treated and I have a metal biliary stent.I have inflammatory bowel disease (Crohn's or ulcerative colitis).I have had cancer before, but it was either skin cancer treated successfully, cervical cancer that did not spread, or another type with a low risk of coming back.
- Group 1: Low Risk UGT1A1 genotype
- Group 2: High Risk UGT1A1 genotype
- Group 3: Intermediate Risk UGT1A1 genotype
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Approved for 10 Other Conditions - This treatment demonstrated efficacy for 10 other conditions.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Could you provide information about any prior experiments with Irinotecan?
"Presently, there are 901 ongoing studies for Irinotecan with 303 trials in their last phase. Most of these tests take place within Guangzhou, Guangdong; however, a total of 47864 sites worldwide are running clinical trials involving this medication."
Is enrollment in this clinical experiment still available?
"Affirmative. According to the clinicaltrials.gov information, this study is presently open for recruitment - first posted on 8th May 2020 and last updated 7th June 2021. 54 participants are sought from one medical centre."
What is the total enrollment count for this clinical research?
"Affirmative, clinicaltrials.gov indicates that this trial is in its active recruitment phase. The study was initially posted on May 8th 2020 and last amended on June 7th 2021; 54 participants are needed at 1 medical centre for the venture to proceed."
What risks could be associated with administering Irinotecan?
"With limited data regarding Irinotecan's efficacy and safety, it received a rating of 1 on our team at Power's scale."
What medical conditions has Irinotecan been shown to help with?
"Irinotecan is typically used to manage actinic keratosis, but it also has an indication for soft tissue sarcoma (STS), macrocytic anemia, and various malignant neoplasms."
Share this study with friends
Copy Link
Messenger